{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T04:51:48Z","timestamp":1794718308281,"version":"4.9.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat. Biomed. Eng"],"DOI":"10.1038\/s41551-025-01552-z","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T10:01:45Z","timestamp":1764324105000},"page":"647-659","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["mRNA engineering of allogeneic mesenchymal stem cells enables coordinated delivery of T cell engagers and immunotherapeutic cues"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7936-447X","authenticated-orcid":false,"given":"C. Andrew","family":"Stewart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaji","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4452-0457","authenticated-orcid":false,"given":"Elizabeth J.","family":"Curvino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hafsa","family":"Kamboh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirill","family":"Sergueev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minhtran N.","family":"Casi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4794-6751","authenticated-orcid":false,"given":"Adam","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youqiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Tosun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew T.","family":"Duvernay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufei","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mame","family":"Djigal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Kireeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Biaksangi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor","family":"Glassband","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fevzi","family":"Altuntas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tu\u011f\u00e7e Nur","family":"Yi\u011feno\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Boccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"Bardeja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamna","family":"Wangjam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat V.","family":"Kalayoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Metin","family":"Kurtoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albina","family":"Benson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1621-4669","authenticated-orcid":false,"given":"Emily P.","family":"English","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9255-5684","authenticated-orcid":false,"given":"Lisa H.","family":"Tostanoski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5848-6320","authenticated-orcid":false,"given":"Milos D.","family":"Miljkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6668-6928","authenticated-orcid":false,"given":"Christopher M.","family":"Jewell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"1552_CR1","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","volume":"614","author":"L Labanieh","year":"2023","unstructured":"Labanieh, L. & Mackall, C. L. CAR immune cells: design principles, resistance and the next generation. Nature 614, 635\u2013648 (2023).","journal-title":"Nature"},{"key":"1552_CR2","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June, C. H., O\u2019Connor, R. S., Kawalekar, O. U., Ghassemi, S. & Milone, M. C. CAR T cell immunotherapy for human cancer. Science 359, 1361\u20131365 (2018).","journal-title":"Science"},{"key":"1552_CR3","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park, J. H. et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N. Engl. J. Med. 378, 449\u2013459 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1552_CR4","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1200\/JCO.22.02345","volume":"41","author":"RA Gardner","year":"2023","unstructured":"Gardner, R. A. & Shah, N. N. CAR T-cells for cure in pediatric B-ALL. J. Clin. Oncol. 41, 1646\u20131648 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1552_CR5","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384, 705\u2013716 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1552_CR6","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/JCO.22.00842","volume":"41","author":"T Martin","year":"2023","unstructured":"Martin, T. et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J. Clin. Oncol. 41, 1265\u20131274 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1552_CR7","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/s41586-023-06243-w","volume":"619","author":"DJ Baker","year":"2023","unstructured":"Baker, D. J., Arany, Z., Baur, J. A., Epstein, J. A. & June, C. H. CAR T therapy beyond cancer: the evolution of a living drug. Nature 619, 707\u2013715 (2023).","journal-title":"Nature"},{"key":"1552_CR8","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","volume":"22","author":"V Granit","year":"2023","unstructured":"Granit, V. et al. Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study. Lancet Neurol. 22, 578\u2013590 (2023).","journal-title":"Lancet Neurol."},{"key":"1552_CR9","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Mackensen","year":"2022","unstructured":"Mackensen, A. et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat. Med. 28, 2124\u20132132 (2022).","journal-title":"Nat. Med."},{"key":"1552_CR10","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/s41571-022-00607-3","volume":"19","author":"L Amini","year":"2022","unstructured":"Amini, L. et al. Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion. Nat. Rev. Clin. Oncol. 19, 342\u2013355 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1552_CR11","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41434-018-0019-6","volume":"25","author":"KL Lowe","year":"2018","unstructured":"Lowe, K. L. et al. Fludarabine and neurotoxicity in engineered T-cell therapy. Gene Ther. 25, 176\u2013191 (2018).","journal-title":"Gene Ther."},{"key":"1552_CR12","doi-asserted-by":"publisher","first-page":"S253","DOI":"10.37765\/ajmc.2021.88737","volume":"27","author":"R Borgert","year":"2021","unstructured":"Borgert, R. Improving outcomes and mitigating costs associated with CAR T-cell therapy. Am. J. Manag. Care 27, S253\u2013S261 (2021).","journal-title":"Am. J. Manag. Care"},{"key":"1552_CR13","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.stem.2023.02.009","volume":"30","author":"Y-R Li","year":"2023","unstructured":"Li, Y.-R. et al. Advancing cell-based cancer immunotherapy through stem cell engineering. Cell Stem Cell 30, 592\u2013610 (2023).","journal-title":"Cell Stem Cell"},{"key":"1552_CR14","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1186\/s13287-022-03054-0","volume":"13","author":"R Margiana","year":"2022","unstructured":"Margiana, R. et al. Clinical application of mesenchymal stem cell in regenerative medicine: a narrative review. Stem Cell Res. Ther. 13, 366 (2022).","journal-title":"Stem Cell Res. Ther."},{"key":"1552_CR15","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1177\/0963689719837897","volume":"28","author":"A Musia\u0142-Wysocka","year":"2019","unstructured":"Musia\u0142-Wysocka, A., Kot, M. & Majka, M. The pros and cons of mesenchymal stem cell-based therapies. Cell Transplant. 28, 801\u2013812 (2019).","journal-title":"Cell Transplant."},{"key":"1552_CR16","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.stem.2018.05.004","volume":"22","author":"J Galipeau","year":"2018","unstructured":"Galipeau, J. & Sensebe, L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell 22, 824\u2013833 (2018).","journal-title":"Cell Stem Cell"},{"key":"1552_CR17","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41536-019-0083-6","volume":"4","author":"MF Pittenger","year":"2019","unstructured":"Pittenger, M. F. et al. Mesenchymal stem cell perspective: cell biology to clinical progress. npj Regen. Med. 4, 22 (2019).","journal-title":"npj Regen. Med."},{"key":"1552_CR18","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1038\/s41375-020-0951-5","volume":"35","author":"L Lin","year":"2021","unstructured":"Lin, L. et al. Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma. Leukemia 35, 752\u2013763 (2021).","journal-title":"Leukemia"},{"key":"1552_CR19","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/imr.12233","volume":"263","author":"Y Kawano","year":"2015","unstructured":"Kawano, Y. et al. Targeting the bone marrow microenvironment in multiple myeloma. Immunol. Rev. 263, 160\u2013172 (2015).","journal-title":"Immunol. Rev."},{"key":"1552_CR20","doi-asserted-by":"publisher","first-page":"8975","DOI":"10.3390\/curroncol29110705","volume":"29","author":"M Ho","year":"2022","unstructured":"Ho, M., Xiao, A., Yi, D., Zanwar, S. & Bianchi, G. Treating multiple myeloma in the context of the bone marrow microenvironment. Curr. Oncol. 29, 8975\u20139005 (2022).","journal-title":"Curr. Oncol."},{"key":"1552_CR21","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/mt.2010.313","volume":"19","author":"L Zhang","year":"2011","unstructured":"Zhang, L. et al. Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. Mol. Ther. 19, 751\u2013759 (2011).","journal-title":"Mol. Ther."},{"key":"1552_CR22","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/S1074-7613(03)00296-6","volume":"19","author":"G Trinchieri","year":"2003","unstructured":"Trinchieri, G., Pflanz, S. & Kastelein, R. A. The IL-12 family of heterodimeric cytokines. Immunity 19, 641\u2013644 (2003).","journal-title":"Immunity"},{"key":"1552_CR23","doi-asserted-by":"publisher","first-page":"106","DOI":"10.7150\/thno.16911","volume":"7","author":"L Liao","year":"2017","unstructured":"Liao, L. et al. Heparin improves BMSC cell therapy: anticoagulant treatment by heparin improves the safety and therapeutic effect of bone marrow-derived mesenchymal stem cell cytotherapy. Theranostics 7, 106\u2013116 (2017).","journal-title":"Theranostics"},{"key":"1552_CR24","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s12185-017-2213-5","volume":"106","author":"T Ishihara","year":"2017","unstructured":"Ishihara, T. et al. Potentially life-threatening coagulopathy associated with simultaneous reduction in coagulation and fibrinolytic function in pediatric acute leukemia after hematopoietic stem-cell transplantation. Int. J. Hematol. 106, 126\u2013134 (2017).","journal-title":"Int. J. Hematol."},{"key":"1552_CR25","first-page":"2541","volume":"90","author":"JP Leonard","year":"1997","unstructured":"Leonard, J. P. et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 90, 2541\u20132548 (1997).","journal-title":"Blood"},{"key":"1552_CR26","doi-asserted-by":"publisher","unstructured":"Ding, H. et al. The repeated administration of rhIL-12 for 14\u2009weeks in rhesus monkeys: a toxicity assessment. J. Appl. Toxicol. https:\/\/doi.org\/10.1002\/jat.4541 (2023).","DOI":"10.1002\/jat.4541"},{"key":"1552_CR27","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1089\/ten.tec.2007.0359","volume":"14","author":"MF Ryser","year":"2008","unstructured":"Ryser, M. F. et al. mRNA transfection of CXCR4-GFP fusion\u2014simply generated by PCR\u2014results in efficient migration of primary human mesenchymal stem cells. Tissue Eng. C 14, 179\u2013184 (2008).","journal-title":"Tissue Eng. C"},{"key":"1552_CR28","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1182\/blood-2013-04-495119","volume":"122","author":"O Levy","year":"2013","unstructured":"Levy, O. et al. mRNA-engineered mesenchymal stem cells for targeted delivery of interleukin-10 to sites of inflammation. Blood 122, e23\u2013e32 (2013).","journal-title":"Blood"},{"key":"1552_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s13036-019-0140-0","volume":"13","author":"A Hamann","year":"2019","unstructured":"Hamann, A., Nguyen, A. & Pannier, A. K. Nucleic acid delivery to mesenchymal stem cells: a review of nonviral methods and applications. J. Biol. Eng. 13, 7 (2019).","journal-title":"J. Biol. Eng."},{"key":"1552_CR30","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.ado2084","volume":"16","author":"EP English","year":"2024","unstructured":"English, E. P. et al. Engineering CAR-T therapies for autoimmune disease and beyond. Sci. Transl. Med. 16, eado2084 (2024).","journal-title":"Sci. Transl. Med."},{"key":"1552_CR31","doi-asserted-by":"publisher","unstructured":"Chahin, N. et al. Durability of Response to B-Cell Maturation Antigen-Directed mRNA Cell Therapy in Myasthenia Gravis. Ann. Clin. Transl Neurol. https:\/\/doi.org\/10.1002\/acn3.70167 (2025).","DOI":"10.1002\/acn3.70167"},{"key":"1552_CR32","doi-asserted-by":"publisher","first-page":"eaba6884","DOI":"10.1126\/sciadv.aba6884","volume":"6","author":"O Levy","year":"2020","unstructured":"Levy, O. et al. Shattering barriers toward clinically meaningful MSC therapies. Sci. Adv. 6, eaba6884 (2020).","journal-title":"Sci. Adv."},{"key":"1552_CR33","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1186\/s13287-018-1078-8","volume":"9","author":"I Christodoulou","year":"2018","unstructured":"Christodoulou, I. et al. Mesenchymal stem cells in preclinical cancer cytotherapy: a systematic review. Stem Cell Res. Ther. 9, 336 (2018).","journal-title":"Stem Cell Res. Ther."},{"key":"1552_CR34","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1002\/stem.645","volume":"29","author":"MR Reagan","year":"2011","unstructured":"Reagan, M. R. & Kaplan, D. L. Concise review: mesenchymal stem cell tumor-homing: detection methods in disease model systems. Stem Cells 29, 920\u2013927 (2011).","journal-title":"Stem Cells"},{"key":"1552_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/130763","volume":"2013","author":"A Sohni","year":"2013","unstructured":"Sohni, A. & Verfaillie, C. M. Mesenchymal stem cells migration homing and tracking. Stem Cells Int. 2013, 1\u20138 (2013).","journal-title":"Stem Cells Int."},{"key":"1552_CR36","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.jmb.2007.02.100","volume":"369","author":"KR Abhinandan","year":"2007","unstructured":"Abhinandan, K. R. & Martin, A. C. R. Analyzing the \u2018degree of humanness\u2019 of antibody sequences. J. Mol. Biol. 369, 852\u2013862 (2007).","journal-title":"J. Mol. Biol."}],"container-title":["Nature Biomedical Engineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01552-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01552-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01552-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T22:02:41Z","timestamp":1776808961000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01552-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":36,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["1552"],"URL":"https:\/\/doi.org\/10.1038\/s41551-025-01552-z","relation":{},"ISSN":["2157-846X"],"issn-type":[{"value":"2157-846X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"21 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.A.S., S.D., E.J.C., Y.Z., H.K., K.S., M.N.C., A.C., H.X., Y.L., M.T., M.T.D., Y.S., M.D., M.K., J.L.B., T.G., M.S.S., M.V.K., M.K., A.B., E.P.E., L.H.T., M.D.M. and C.M.J. are employees of and\/or hold equity in Cartesian Therapeutics. C.M.J. is appointed as a professor at the University of Maryland and a research health scientist at the VA Maryland Health Care System. The views in this paper do not reflect the views of the state of Maryland or the United States Government. C.M.J. is founder of Nodal Therapeutics and holds equity positions with Nodal Therapeutics and Barinthus Biotherapeutics. J.B.\u2019s institution receives research funds in their name from AstraZeneca, BMS, C4 Therapeutics, Caribou Biosciences, CARsgen, Cartesian Therapeutics, Genentech, GSK, Gracell, Ichnos Sciences, J&J, Juno Therapeutics, K36 Therapeutics, Karyopharm, Kite, Moderna, Pfizer, Regeneron, Roche and Sanofi. J.B. is a consultant for AstraZeneca, BMS, Galapagos, Genentech, J&J, Karyopharm, Kite Pharma, Kyowa Kirin, Pfizer, Regeneron, Roche and Sebia. J.B. has received a speaker honorarium from Janssen. No other conflicts are declared.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}